CEOs at large pharma and biotech companies are upbeat when it comes to their outlook for both their own company and the industry at large; they also have a healthy appetite for M&A, found a KPMG survey.
Gamma Biosciences has taken a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Wisconsin in the US.
Aldevron announces the expansion of its headquarters’ campus by half a million-square-feet, which will see annual capacity exceed $1bn of biologic products.
Agilent Technologies is expanding its nucleic acid active
pharmaceutical ingredient (API) manufacturing facility in Boulder,
Colorado, US, as the industry gravitates towards the
development of oligonucleotide-based drugs.
Invitrogen, which supplies reagents, services and software for the
life science market, has continued its acquisitive streak with the
announcement that it is paying $35 million (€27.5m) for a UK firm -
DNA Research Innovations - specialising...